MIST vs. TECX, ORGO, ERAS, ZVRA, AKBA, RVNC, PRME, ORKA, TKNO, and ETON
Should you be buying Milestone Pharmaceuticals stock or one of its competitors? The main competitors of Milestone Pharmaceuticals include Tectonic Therapeutic (TECX), Organogenesis (ORGO), Erasca (ERAS), Zevra Therapeutics (ZVRA), Akebia Therapeutics (AKBA), Revance Therapeutics (RVNC), Prime Medicine (PRME), Oruka Therapeutics (ORKA), Alpha Teknova (TKNO), and Eton Pharmaceuticals (ETON). These companies are all part of the "pharmaceutical products" industry.
Milestone Pharmaceuticals vs.
Tectonic Therapeutic (NASDAQ:TECX) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership, community ranking and dividends.
Tectonic Therapeutic has higher earnings, but lower revenue than Milestone Pharmaceuticals. Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Tectonic Therapeutic has a beta of 2.62, indicating that its share price is 162% more volatile than the S&P 500. Comparatively, Milestone Pharmaceuticals has a beta of 1.8, indicating that its share price is 80% more volatile than the S&P 500.
Tectonic Therapeutic currently has a consensus price target of $80.50, indicating a potential upside of 243.87%. Milestone Pharmaceuticals has a consensus price target of $13.00, indicating a potential upside of 687.88%. Given Milestone Pharmaceuticals' higher probable upside, analysts clearly believe Milestone Pharmaceuticals is more favorable than Tectonic Therapeutic.
In the previous week, Milestone Pharmaceuticals had 3 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 7 mentions for Milestone Pharmaceuticals and 4 mentions for Tectonic Therapeutic. Tectonic Therapeutic's average media sentiment score of 1.10 beat Milestone Pharmaceuticals' score of 0.49 indicating that Tectonic Therapeutic is being referred to more favorably in the media.
Tectonic Therapeutic's return on equity of -35.53% beat Milestone Pharmaceuticals' return on equity.
Milestone Pharmaceuticals received 75 more outperform votes than Tectonic Therapeutic when rated by MarketBeat users. However, 100.00% of users gave Tectonic Therapeutic an outperform vote while only 69.75% of users gave Milestone Pharmaceuticals an outperform vote.
62.6% of Tectonic Therapeutic shares are held by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are held by institutional investors. 9.2% of Tectonic Therapeutic shares are held by company insiders. Comparatively, 9.9% of Milestone Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Tectonic Therapeutic beats Milestone Pharmaceuticals on 9 of the 17 factors compared between the two stocks.
Get Milestone Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for MIST and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Milestone Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:MIST) was last updated on 3/4/2025 by MarketBeat.com Staff
Free MIST Stock Alerts